How fast should tirzepatide work?
Initial loss in 2-4 weeks; substantial loss requires therapeutic doses.
Is 5 mg enough?
15.0% mean loss in SURMOUNT-1 over 72 weeks; meaningful but not maximal.
Should I be at 15 mg?
Not necessarily; depends on response and tolerability.
Why did I plateau early?
Apparent early plateau is often not true plateau; usually resolves with assessment.
Does tirzepatide work better than semaglutide?
Higher mean weight loss in trials; individual response varies.
Can exercise break the plateau?
Resistance training preserves muscle and supports continued progress.
What if my dose was reduced?
Progress may slow; discuss re-titration with prescriber.
Could I be a non-responder?
~14% of SURMOUNT-1 patients lost under 5%; biological variation is real.
Should I add another medication?
Combination therapy isn't commonly evidence-based for tirzepatide; discuss with prescriber.
Related guides
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Wegovy? The Six Levers Worth Pulling
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Not Losing Weight on Ozempic: A Troubleshooting Checklist
Sources
- Jastreboff AM et al., SURMOUNT-1, NEJM July 2022
- Aronne LJ et al., SURMOUNT-4, JAMA January 2024
- Mounjaro FDA prescribing information
- Zepbound FDA prescribing information
- Wilding JPH et al., STEP 1, NEJM March 2021
- Tasali E et al., JAMA Internal Medicine March 2022
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- American Thyroid Association screening guidelines
- ACSM resistance training guidelines
- National Sleep Foundation recommendations
- CDC alcohol use guidelines
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians. This article is educational. Clinical decisions involve individual assessment by your prescriber.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. SURMOUNT trial data applies to brand product specifically.
Results Disclaimer. Outcomes vary substantially. SURMOUNT-1 mean represents group average; individual results range from minimal to 30%+ loss. Your result depends on dose, adherence, baseline, lifestyle, and physiology.
Trademark Notice. Mounjaro, Zepbound, and SURMOUNT are trademarks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →